SCHEMBL2497645

SCHEMBL2497645

O=C(Cl)c1cn(-c2cccc(-c3ccnc(F)c3)c2)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.39
MLLT3 P42568 1/20 0.38
MLLT1 Q03111 1/20 0.38
CTSA P10619 1/20 0.37
NOTUM Q6P988 1/20 0.36
ROCK2 O75116 2/20 0.35
MAP3K5 Q99683 4/20 0.35
CYP2C9 P11712 1/20 0.33
PRKACA P17612 1/20 0.33
PRKACG P22612 1/20 0.33
PRKACB P22694 1/20 0.33
AKT1 P31749 1/20 0.33
ROCK1 Q13464 1/20 0.33
PRKG1 Q13976 1/20 0.33
COMT P21964 1/20 0.33
USP30 Q70CQ3 1/20 0.32
CAPN1 P07384 1/20 0.32
ITGA2B P08514 1/20 0.32
GRM5 P41594 1/20 0.32
CNR2 P34972 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1878814 0.89 KDM4E (0.43) DHFRMLLT3MLLT1CTSAKDM4E
SCHEMBL2497361 0.84 COMT (0.46) MLLT3MLLT1NOTUMCOMTUSP30
SCHEMBL2495463 0.83 MLLT3 (0.37) MLLT3MLLT1NOTUMMAP3K5GRM5
SCHEMBL1880213 0.82 NOTUM (0.56) NOTUMGRM5
SCHEMBL2498043 0.81 TRPM8 (0.36) DHFRMLLT3MLLT1CTSANOTUM
SCHEMBL2493511 0.81 CYP11B2 (0.38) MLLT3MLLT1NOTUM
SCHEMBL2498039 0.80 USP30 (0.45) DHFRMLLT3MLLT1CTSANOTUM
SCHEMBL2501423 0.77 CTSA (0.40) MLLT3MLLT1CTSANOTUMGRM5
SCHEMBL2503558 0.77 SCN9A (0.49) MLLT3MLLT1CTSANOTUMGRM5
SCHEMBL2493418 0.75 SCN9A (0.43) CTSANOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030339-B2 Imidazole derivatives for the treatment of anxiety and related diseases NEUROSEARCH A/S (DK) 2011-10-04 US disclosed
US-20090233929-A1 Imidazole Derivatives for the Treatment of Anxiety and Related Diseases NEUROSEARCH A/S (DK) 2009-09-17 US disclosed
CN-101282942-A Imidazole derivatives for the treatment of anxiety and related diseases NEUROSEARCH AS (DK) 2008-10-08 CN disclosed
EP-1937649-A1 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES NEUROSEARCH A/S (DK) 2008-07-02 EP disclosed
WO-2007042546-A1 IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES NEUROSEARCH A/S (DK) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233929-A1 Imidazole Derivatives for the Treatment of Anxiety and Related Diseases GABBR1, GABRB2, GABRB3 DHFR 3315/4885MLLT3 3352/4885MLLT1 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.